Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transc

U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent

UBS analyst Dan Leonard maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target

Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (NASDAQ:BRKR), and

10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Bioscien

Citigroup analyst Brendan Digan maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the pric

The S&P 500 and Dow set records as Palantir and Caterpillar earnings powered chips higher, while

Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular se

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday'

Bruker (NASDAQ:BRKR) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analys

Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.49 per share which beat the analyst consensus

Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-mar

The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehens

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the p

Leerink Partners analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises

Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price tar

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the pri

Bruker CorporationCommon StockPreferred StockDebt SecuritiesWarrantsUnitsDepositary SharesSubscripti

At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostic

Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry

World's highest-field MRI system provides leading disease biology research capabilitiesBruker Co

UBS analyst Dan Leonard maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the p

TD Cowen analyst Kyle Boucher maintains Bruker (NASDAQ:BRKR) with a Hold and raises the price tar

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the pri

Bruker (NASDAQ:BRKR) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analys

Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.31 per share which beat the analyst consensus

MALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and lowers the pri

The introductions span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and

Bruker Corporation (NASDAQ:BRKR) today announced accelerated development of its photothermal AFM-IR

Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and lowers the price tar

Novel timsOmni workflows enable deeper functional characterization of proteoforms and PTMs, leveragi

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the p

Goldman Sachs analyst Evie Koslosky maintains Bruker (NASDAQ:BRKR) with a Sell and lowers the pri

TD Cowen analyst Dan Brennan maintains Bruker (NASDAQ:BRKR) with a Hold and lowers the price targ

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and lowers the pri

Bruker (NASDAQ:BRKR) is looking for FY2026 Adj EPS of $2.10-$2.15 vs $2.13 analyst estimate. sees sa

Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.59 per share which missed the analyst consens

Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price tar

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the p

Wall Street traded timidly on Tuesday despite another benign inflation report that reinforced expect

Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, during its scheduled p